Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 25, 2024 5:11pm
66 Views
Post# 36241044

RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerThe reported incidence of breast cancer is currently based on 2022 numbers,which approximates 685,700 women being diagnosed with invasive breast cancer just in the United States and the EU -27.

On 2022 global numbers -  HR+/HER2 negative breasat cancer accounts for approximately 65% of all breast cancers (60-70%), thus translating into approximately 446,000 women who are diagnosed each year with HR+/HER2 negative breast cancer in the US and EU-27.


Out of the approximate 446,000  women newly diagnosed HR+/HER2 negative breast cancer each year, ONCY has estimated that approximately 55,000 of these women will progress to 3rd line mBC therapy which ONCY has stated will be eligible for pelareorep (monotherapy) + paclitaxel treatment.
<< Previous
Bullboard Posts
Next >>